Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies

Aims: To evaluate efficacy and safety in patients with ocular hypertension or open angle glaucoma changed to latanoprost/timolol fixed combination (LTFC). Methods: A prospective, multicentre, historical control in which qualified patients had their previous therapy substituted by LTFC and were follo...

Full description

Saved in:
Bibliographic Details
Published in:British journal of ophthalmology 2004-10, Vol.88 (10), p.1295-1298
Main Authors: Hamacher, T, Schinzel, M, Schölzel-Klatt, A, Neff, H-M, Maier, H, Schlaffer, G, Beausencourt, E, Jütte, M, Scholz, R, Lorger, C, Stewart, W C
Format: Article
Language:English
Subjects:
Aged
Antihypertensive Agents - adverse effects
Antihypertensive Agents - therapeutic use
Biological and medical sciences
CAI
carbonic anhydrase inhibitors
Clinical medicine
Clinical Science - Extended Reports
Clinical trials
Compliance
Data analysis
Data collection
Drug Combinations
Drug dosages
Female
Glaucoma
Glaucoma and intraocular pressure
Glaucoma, Open-Angle - drug therapy
Glaucoma, Open-Angle - physiopathology
Humans
Hypertension
intraocular pressure
Intraocular Pressure - drug effects
IOP
latanoprost/timolol fixed combination
latanoprost/timolol maleate fixed combination
LTFC
Male
Medical sciences
Middle Aged
Ocular Hypertension - drug therapy
Ocular Hypertension - physiopathology
Ophthalmology
Prospective Studies
Prostaglandins F, Synthetic - adverse effects
Prostaglandins F, Synthetic - therapeutic use
Studies
Timolol - adverse effects
Timolol - therapeutic use
Treatment Failure
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b586t-d9570606b5516e8fe3aaf4aa7d8f49a96a79ec6c8119a4296960603346138e5a3
cites
container_end_page 1298
container_issue 10
container_start_page 1295
container_title British journal of ophthalmology
container_volume 88
creator Hamacher, T
Schinzel, M
Schölzel-Klatt, A
Neff, H-M
Maier, H
Schlaffer, G
Beausencourt, E
Jütte, M
Scholz, R
Lorger, C
Stewart, W C
description Aims: To evaluate efficacy and safety in patients with ocular hypertension or open angle glaucoma changed to latanoprost/timolol fixed combination (LTFC). Methods: A prospective, multicentre, historical control in which qualified patients had their previous therapy substituted by LTFC and were followed for at least 2 months. Results: In 1676 patients LTFC was continued in 93% throughout the observation period. In all patients LTFC reduced the intraocular pressure (IOP) from 20.6 (SD 3.8) to 17.7 (3.0) mm Hg (p
doi_str_mv 10.1136/bjo.2004.043232
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1772363</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4012374191</sourcerecordid><originalsourceid>FETCH-LOGICAL-b586t-d9570606b5516e8fe3aaf4aa7d8f49a96a79ec6c8119a4296960603346138e5a3</originalsourceid><addsrcrecordid>eNqFkU-P0zAQxSMEYsvCmRuyhHpBSmvHsR1fkFAFu4sqQOLPgYs1cZzWJbGL7a6234iPiUurLpw4Wfb7zZsZv6J4TvCMEMrn7cbPKozrGa5pRasHxYTUvCkrLOTDYoIxFiUhnFwUT2Lc5GvFiXhcXBBGhWCsnhS_Pq99SCiZMCLT91aD3iNwHYrQm7RH1qHVADvtR0BbSNa4FJFeg1uZDiWP0tqgARI4vw0-JoRnGLPpPNnRD35AIwwGksnPbIp6e5eLslVrXbbyDvXBj2j0zmebAFtr4p_e0G12Tid7a9BZeFo86mGI5tnpvCy-vnv7ZXFdLj9e3SzeLMuWNTyVnWQCc8xbxgg3TW8oQF8DiK7pawmSg5BGc90QIqGuJJcZxpTWnNDGMKCXxeuj73bXjqbTeeEAg9oGO0LYKw9W_as4u1Yrf6uIEBXlNBu8PBkE_3NnYlIbvwsuz3xAGkmwZE2m5kdK52-LwfTnDgSrQ7QqR6sO0apjtLnixd-D3fOnLDMwPQEQNQx9AKdtvOc4YZXgLHPlkbMxmbuzDuGH4oIKpj58W6jl9_dEyE9MXWX-1ZFvx81_p_wND67K0w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1778910958</pqid></control><display><type>article</type><title>Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies</title><source>PubMed Central</source><creator>Hamacher, T ; Schinzel, M ; Schölzel-Klatt, A ; Neff, H-M ; Maier, H ; Schlaffer, G ; Beausencourt, E ; Jütte, M ; Scholz, R ; Lorger, C ; Stewart, W C</creator><creatorcontrib>Hamacher, T ; Schinzel, M ; Schölzel-Klatt, A ; Neff, H-M ; Maier, H ; Schlaffer, G ; Beausencourt, E ; Jütte, M ; Scholz, R ; Lorger, C ; Stewart, W C</creatorcontrib><description>Aims: To evaluate efficacy and safety in patients with ocular hypertension or open angle glaucoma changed to latanoprost/timolol fixed combination (LTFC). Methods: A prospective, multicentre, historical control in which qualified patients had their previous therapy substituted by LTFC and were followed for at least 2 months. Results: In 1676 patients LTFC was continued in 93% throughout the observation period. In all patients LTFC reduced the intraocular pressure (IOP) from 20.6 (SD 3.8) to 17.7 (3.0) mm Hg (p&lt;0.001) compared to previous monotherapies including latanoprost, timolol, α agonists or carbonic anhydrase inhibitors (CAI). LTFC provided more efficacy after changing from adjunctive therapies including: a β blocker added to either CAI, α agonist, or pilocarpine, or CAI added to an α agonist, or latanoprost added to either CAI, α agonist, or β blocker (unfixed combination), and travoprost added to timolol (p&lt;0.007). LTFC was as effective as latanoprost used with dorzolamide/timolol fixed combination (−0.9 mm Hg, p = 0.1792). The most common reason to discontinue therapy was lack of efficacy (n = 70, 4%) and adverse event (n = 17, 1%). Conclusion: In a clinical setting, patients who have their monotherapy or adjunctive therapy substituted with LTFC may experience reduced IOP, good tolerability, and continuation of therapy for the first 2–3 months of treatment.</description><identifier>ISSN: 0007-1161</identifier><identifier>EISSN: 1468-2079</identifier><identifier>DOI: 10.1136/bjo.2004.043232</identifier><identifier>PMID: 15377554</identifier><identifier>CODEN: BJOPAL</identifier><language>eng</language><publisher>BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd</publisher><subject>Aged ; Antihypertensive Agents - adverse effects ; Antihypertensive Agents - therapeutic use ; Biological and medical sciences ; CAI ; carbonic anhydrase inhibitors ; Clinical medicine ; Clinical Science - Extended Reports ; Clinical trials ; Compliance ; Data analysis ; Data collection ; Drug Combinations ; Drug dosages ; Female ; Glaucoma ; Glaucoma and intraocular pressure ; Glaucoma, Open-Angle - drug therapy ; Glaucoma, Open-Angle - physiopathology ; Humans ; Hypertension ; intraocular pressure ; Intraocular Pressure - drug effects ; IOP ; latanoprost/timolol fixed combination ; latanoprost/timolol maleate fixed combination ; LTFC ; Male ; Medical sciences ; Middle Aged ; Ocular Hypertension - drug therapy ; Ocular Hypertension - physiopathology ; Ophthalmology ; Prospective Studies ; Prostaglandins F, Synthetic - adverse effects ; Prostaglandins F, Synthetic - therapeutic use ; Studies ; Timolol - adverse effects ; Timolol - therapeutic use ; Treatment Failure ; Treatment Outcome</subject><ispartof>British journal of ophthalmology, 2004-10, Vol.88 (10), p.1295-1298</ispartof><rights>Copyright 2004 British Journal of Ophthalmology</rights><rights>2004 INIST-CNRS</rights><rights>Copyright: 2004 Copyright 2004 British Journal of Ophthalmology</rights><rights>Copyright © Copyright 2004 British Journal of Ophthalmology 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b586t-d9570606b5516e8fe3aaf4aa7d8f49a96a79ec6c8119a4296960603346138e5a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1772363/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1772363/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16152765$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15377554$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hamacher, T</creatorcontrib><creatorcontrib>Schinzel, M</creatorcontrib><creatorcontrib>Schölzel-Klatt, A</creatorcontrib><creatorcontrib>Neff, H-M</creatorcontrib><creatorcontrib>Maier, H</creatorcontrib><creatorcontrib>Schlaffer, G</creatorcontrib><creatorcontrib>Beausencourt, E</creatorcontrib><creatorcontrib>Jütte, M</creatorcontrib><creatorcontrib>Scholz, R</creatorcontrib><creatorcontrib>Lorger, C</creatorcontrib><creatorcontrib>Stewart, W C</creatorcontrib><title>Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies</title><title>British journal of ophthalmology</title><addtitle>Br J Ophthalmol</addtitle><description>Aims: To evaluate efficacy and safety in patients with ocular hypertension or open angle glaucoma changed to latanoprost/timolol fixed combination (LTFC). Methods: A prospective, multicentre, historical control in which qualified patients had their previous therapy substituted by LTFC and were followed for at least 2 months. Results: In 1676 patients LTFC was continued in 93% throughout the observation period. In all patients LTFC reduced the intraocular pressure (IOP) from 20.6 (SD 3.8) to 17.7 (3.0) mm Hg (p&lt;0.001) compared to previous monotherapies including latanoprost, timolol, α agonists or carbonic anhydrase inhibitors (CAI). LTFC provided more efficacy after changing from adjunctive therapies including: a β blocker added to either CAI, α agonist, or pilocarpine, or CAI added to an α agonist, or latanoprost added to either CAI, α agonist, or β blocker (unfixed combination), and travoprost added to timolol (p&lt;0.007). LTFC was as effective as latanoprost used with dorzolamide/timolol fixed combination (−0.9 mm Hg, p = 0.1792). The most common reason to discontinue therapy was lack of efficacy (n = 70, 4%) and adverse event (n = 17, 1%). Conclusion: In a clinical setting, patients who have their monotherapy or adjunctive therapy substituted with LTFC may experience reduced IOP, good tolerability, and continuation of therapy for the first 2–3 months of treatment.</description><subject>Aged</subject><subject>Antihypertensive Agents - adverse effects</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>CAI</subject><subject>carbonic anhydrase inhibitors</subject><subject>Clinical medicine</subject><subject>Clinical Science - Extended Reports</subject><subject>Clinical trials</subject><subject>Compliance</subject><subject>Data analysis</subject><subject>Data collection</subject><subject>Drug Combinations</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Glaucoma</subject><subject>Glaucoma and intraocular pressure</subject><subject>Glaucoma, Open-Angle - drug therapy</subject><subject>Glaucoma, Open-Angle - physiopathology</subject><subject>Humans</subject><subject>Hypertension</subject><subject>intraocular pressure</subject><subject>Intraocular Pressure - drug effects</subject><subject>IOP</subject><subject>latanoprost/timolol fixed combination</subject><subject>latanoprost/timolol maleate fixed combination</subject><subject>LTFC</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Ocular Hypertension - drug therapy</subject><subject>Ocular Hypertension - physiopathology</subject><subject>Ophthalmology</subject><subject>Prospective Studies</subject><subject>Prostaglandins F, Synthetic - adverse effects</subject><subject>Prostaglandins F, Synthetic - therapeutic use</subject><subject>Studies</subject><subject>Timolol - adverse effects</subject><subject>Timolol - therapeutic use</subject><subject>Treatment Failure</subject><subject>Treatment Outcome</subject><issn>0007-1161</issn><issn>1468-2079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqFkU-P0zAQxSMEYsvCmRuyhHpBSmvHsR1fkFAFu4sqQOLPgYs1cZzWJbGL7a6234iPiUurLpw4Wfb7zZsZv6J4TvCMEMrn7cbPKozrGa5pRasHxYTUvCkrLOTDYoIxFiUhnFwUT2Lc5GvFiXhcXBBGhWCsnhS_Pq99SCiZMCLT91aD3iNwHYrQm7RH1qHVADvtR0BbSNa4FJFeg1uZDiWP0tqgARI4vw0-JoRnGLPpPNnRD35AIwwGksnPbIp6e5eLslVrXbbyDvXBj2j0zmebAFtr4p_e0G12Tid7a9BZeFo86mGI5tnpvCy-vnv7ZXFdLj9e3SzeLMuWNTyVnWQCc8xbxgg3TW8oQF8DiK7pawmSg5BGc90QIqGuJJcZxpTWnNDGMKCXxeuj73bXjqbTeeEAg9oGO0LYKw9W_as4u1Yrf6uIEBXlNBu8PBkE_3NnYlIbvwsuz3xAGkmwZE2m5kdK52-LwfTnDgSrQ7QqR6sO0apjtLnixd-D3fOnLDMwPQEQNQx9AKdtvOc4YZXgLHPlkbMxmbuzDuGH4oIKpj58W6jl9_dEyE9MXWX-1ZFvx81_p_wND67K0w</recordid><startdate>20041001</startdate><enddate>20041001</enddate><creator>Hamacher, T</creator><creator>Schinzel, M</creator><creator>Schölzel-Klatt, A</creator><creator>Neff, H-M</creator><creator>Maier, H</creator><creator>Schlaffer, G</creator><creator>Beausencourt, E</creator><creator>Jütte, M</creator><creator>Scholz, R</creator><creator>Lorger, C</creator><creator>Stewart, W C</creator><general>BMJ Publishing Group Ltd</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><general>Copyright 2004 British Journal of Ophthalmology</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20041001</creationdate><title>Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies</title><author>Hamacher, T ; Schinzel, M ; Schölzel-Klatt, A ; Neff, H-M ; Maier, H ; Schlaffer, G ; Beausencourt, E ; Jütte, M ; Scholz, R ; Lorger, C ; Stewart, W C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b586t-d9570606b5516e8fe3aaf4aa7d8f49a96a79ec6c8119a4296960603346138e5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Antihypertensive Agents - adverse effects</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>CAI</topic><topic>carbonic anhydrase inhibitors</topic><topic>Clinical medicine</topic><topic>Clinical Science - Extended Reports</topic><topic>Clinical trials</topic><topic>Compliance</topic><topic>Data analysis</topic><topic>Data collection</topic><topic>Drug Combinations</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Glaucoma</topic><topic>Glaucoma and intraocular pressure</topic><topic>Glaucoma, Open-Angle - drug therapy</topic><topic>Glaucoma, Open-Angle - physiopathology</topic><topic>Humans</topic><topic>Hypertension</topic><topic>intraocular pressure</topic><topic>Intraocular Pressure - drug effects</topic><topic>IOP</topic><topic>latanoprost/timolol fixed combination</topic><topic>latanoprost/timolol maleate fixed combination</topic><topic>LTFC</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Ocular Hypertension - drug therapy</topic><topic>Ocular Hypertension - physiopathology</topic><topic>Ophthalmology</topic><topic>Prospective Studies</topic><topic>Prostaglandins F, Synthetic - adverse effects</topic><topic>Prostaglandins F, Synthetic - therapeutic use</topic><topic>Studies</topic><topic>Timolol - adverse effects</topic><topic>Timolol - therapeutic use</topic><topic>Treatment Failure</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hamacher, T</creatorcontrib><creatorcontrib>Schinzel, M</creatorcontrib><creatorcontrib>Schölzel-Klatt, A</creatorcontrib><creatorcontrib>Neff, H-M</creatorcontrib><creatorcontrib>Maier, H</creatorcontrib><creatorcontrib>Schlaffer, G</creatorcontrib><creatorcontrib>Beausencourt, E</creatorcontrib><creatorcontrib>Jütte, M</creatorcontrib><creatorcontrib>Scholz, R</creatorcontrib><creatorcontrib>Lorger, C</creatorcontrib><creatorcontrib>Stewart, W C</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hamacher, T</au><au>Schinzel, M</au><au>Schölzel-Klatt, A</au><au>Neff, H-M</au><au>Maier, H</au><au>Schlaffer, G</au><au>Beausencourt, E</au><au>Jütte, M</au><au>Scholz, R</au><au>Lorger, C</au><au>Stewart, W C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies</atitle><jtitle>British journal of ophthalmology</jtitle><addtitle>Br J Ophthalmol</addtitle><date>2004-10-01</date><risdate>2004</risdate><volume>88</volume><issue>10</issue><spage>1295</spage><epage>1298</epage><pages>1295-1298</pages><issn>0007-1161</issn><eissn>1468-2079</eissn><coden>BJOPAL</coden><abstract>Aims: To evaluate efficacy and safety in patients with ocular hypertension or open angle glaucoma changed to latanoprost/timolol fixed combination (LTFC). Methods: A prospective, multicentre, historical control in which qualified patients had their previous therapy substituted by LTFC and were followed for at least 2 months. Results: In 1676 patients LTFC was continued in 93% throughout the observation period. In all patients LTFC reduced the intraocular pressure (IOP) from 20.6 (SD 3.8) to 17.7 (3.0) mm Hg (p&lt;0.001) compared to previous monotherapies including latanoprost, timolol, α agonists or carbonic anhydrase inhibitors (CAI). LTFC provided more efficacy after changing from adjunctive therapies including: a β blocker added to either CAI, α agonist, or pilocarpine, or CAI added to an α agonist, or latanoprost added to either CAI, α agonist, or β blocker (unfixed combination), and travoprost added to timolol (p&lt;0.007). LTFC was as effective as latanoprost used with dorzolamide/timolol fixed combination (−0.9 mm Hg, p = 0.1792). The most common reason to discontinue therapy was lack of efficacy (n = 70, 4%) and adverse event (n = 17, 1%). Conclusion: In a clinical setting, patients who have their monotherapy or adjunctive therapy substituted with LTFC may experience reduced IOP, good tolerability, and continuation of therapy for the first 2–3 months of treatment.</abstract><cop>BMA House, Tavistock Square, London, WC1H 9JR</cop><pub>BMJ Publishing Group Ltd</pub><pmid>15377554</pmid><doi>10.1136/bjo.2004.043232</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1161
ispartof British journal of ophthalmology, 2004-10, Vol.88 (10), p.1295-1298
issn 0007-1161
1468-2079
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1772363
source PubMed Central
subjects Aged
Antihypertensive Agents - adverse effects
Antihypertensive Agents - therapeutic use
Biological and medical sciences
CAI
carbonic anhydrase inhibitors
Clinical medicine
Clinical Science - Extended Reports
Clinical trials
Compliance
Data analysis
Data collection
Drug Combinations
Drug dosages
Female
Glaucoma
Glaucoma and intraocular pressure
Glaucoma, Open-Angle - drug therapy
Glaucoma, Open-Angle - physiopathology
Humans
Hypertension
intraocular pressure
Intraocular Pressure - drug effects
IOP
latanoprost/timolol fixed combination
latanoprost/timolol maleate fixed combination
LTFC
Male
Medical sciences
Middle Aged
Ocular Hypertension - drug therapy
Ocular Hypertension - physiopathology
Ophthalmology
Prospective Studies
Prostaglandins F, Synthetic - adverse effects
Prostaglandins F, Synthetic - therapeutic use
Studies
Timolol - adverse effects
Timolol - therapeutic use
Treatment Failure
Treatment Outcome
title Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T15%3A39%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short%20term%20efficacy%20and%20safety%20in%20glaucoma%20patients%20changed%20to%20the%20latanoprost%200.005%25/timolol%20maleate%200.5%25%20fixed%20combination%20from%20monotherapies%20and%20adjunctive%20therapies&rft.jtitle=British%20journal%20of%20ophthalmology&rft.au=Hamacher,%20T&rft.date=2004-10-01&rft.volume=88&rft.issue=10&rft.spage=1295&rft.epage=1298&rft.pages=1295-1298&rft.issn=0007-1161&rft.eissn=1468-2079&rft.coden=BJOPAL&rft_id=info:doi/10.1136/bjo.2004.043232&rft_dat=%3Cproquest_pubme%3E4012374191%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b586t-d9570606b5516e8fe3aaf4aa7d8f49a96a79ec6c8119a4296960603346138e5a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1778910958&rft_id=info:pmid/15377554&rfr_iscdi=true